
Novo Nordisk slashes Wegovy and Ozempic prices to boost affordability
Novo Nordisk will cut Wegovy by 50% and Ozempic by 35% starting January 2027, setting a $675 per-month price for both drugs and for Rybelsus as well, as it faces competition from Lilly’s Mounjaro/Zepbound and other GLP-1 therapies; the company says the cuts aim to lower out-of-pocket costs for patients with high-deductible plans, and direct-to-patient discounts will remain unchanged.













